{"id":2244,"date":"2026-06-10T09:00:00","date_gmt":"2026-06-10T12:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2244"},"modified":"2026-06-10T09:00:00","modified_gmt":"2026-06-10T12:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-osso-osteossarcoma-ewing-condrossarcoma-endoprotese-mutars","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-osso-osteossarcoma-ewing-condrossarcoma-endoprotese-mutars\/","title":{"rendered":"PGRSS osso: osteossarc, Ewing, condro, endopr"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica osso que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica osso<\/strong> + osteossarcoma adolescente+adulto MAP MTX+Adriamycin+Platinol<\/strong> + Ewing sarcoma EWS-FLI1 t(11;22) VDC\/IE alternating + EPCRH<\/strong> + condrossarcoma G1-G3+desdiferenciado+IDH1\/2<\/strong> + GCT giant cell tumor denosumab Xgeva<\/strong> + ressec\u00e7\u00e3o R0 + endopr\u00f3tese MUTARS Implantcast\/Stanmore Howmedica\/Megaprosthesis Stryker GMRS<\/strong> + bi\u00f3psia core agulha 14G+aberta incisional<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (osteossarcoma + Ewing + condrossarcoma + GCT + cordoma + adamantinoma + linfoma \u00f3sseo + mieloma m\u00faltiplo) + Grupo A4 (linfa regional + tecido mole adjacente + reexcis\u00e3o margem) + Grupo C (Sm-153 EDTMP Quadramet met\u00e1stase \u00f3ssea + Ra-223 Xofigo + I-131 MIBG neuroblastoma + Y-90 SIRT raro) + Grupo E (perfuro bi\u00f3psia core 14G+Tru-Cut+Jamshidi+aberta incisional+Mohs) + Lista C5 (MAP osteossarcoma + VDC\/IE Ewing + denosumab Xgeva GCT + sunitinib+pazopanib sarcoma+regorafenib+ifosfamida+doxorrubicina+trabectedina Yondelis+eribulina Halaven+olaratumab Lartruvo+pembrolizumab Keytruda). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + endopr\u00f3tese MUTARS<\/strong> + subdimensionam denosumab GCT<\/strong> + perdem rastreabilidade tumor \u00f3sseo<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS osso opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (osteossarcoma 35% + Ewing 16% + condrossarcoma 25% + GCT 5% + outros 19%), A4 (ressec\u00e7\u00e3o wide local + reexcis\u00e3o margem + amputa\u00e7\u00e3o), C (Sm-153 EDTMP + Ra-223 + Y-90 + Lu-177 raro), E (bi\u00f3psia core 14G + aberta), Lista C5 (MAP+VDC\/IE+denosumab+sarcoma TKI).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica osso, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos \u00f3sseos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS osso tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 osteossarc+Ewing+condro<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nOST+ES+CS+GCT<\/td>\n<\/tr>\n
A4 ressec\u00e7\u00e3o+endopr\u00f3tese<\/td>\n4-11 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nMUTARS+Stanmore+GMRS<\/td>\n<\/tr>\n
C Sm-153+Ra-223<\/td>\n0,5-1,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nEDTMP+Xofigo+CNEN<\/td>\n<\/tr>\n
E bi\u00f3psia core+aberta<\/td>\n0,4-1,2 kg\/dia<\/td>\nDi\u00e1ria<\/td>\n14G+Tru-Cut+Jamshidi<\/td>\n<\/tr>\n
MAP+VDC\/IE+denosumab<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nLista C5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,4-31,2 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica osso m\u00e9dia porte.<\/p>\n

A1 osteossarcoma + Ewing + condrossarcoma + GCT: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS osso \u00e9 A1. Padr\u00e3o setorial inclui (a) osteossarcoma OST 35%<\/strong> com adolescente+jovem adulto + met\u00e1fise f\u00eamur distal+t\u00edbia proximal+\u00famero proximal + osteobl\u00e1stico+condrobl\u00e1stico+fibrobl\u00e1stico+telangiect\u00e1sico+pequenas c\u00e9lulas+secund\u00e1rio Paget+p\u00f3s-RT; (b) Ewing sarcoma ES 16%<\/strong> com adolescente + di\u00e1fise ossos longos + EWSR1-FLI1 t(11;22) 85% + EWSR1-ERG t(21;22) 10% + extra\u00f3sseo Askin t\u00f3rax + Ki-67 alto + CD99 marker; (c) condrossarcoma CS 25%<\/strong> com adulto meia-idade + bacia 30%+f\u00eamur+\u00famero+esc\u00e1pula + G1 baixo grau + G2-G3 alto grau + desdiferenciado dedifferentiated + mesenquimal+c\u00e9lulas claras + IDH1\/2 muta\u00e7\u00e3o 50%; (d) GCT giant cell tumor 5%<\/strong> com ep\u00edfise p\u00f3s-fechamento placa crescimento + osteoclasto-rico c\u00e9lulas gigantes + RANKL receptor activator + denosumab Xgeva Amgen anti-RANKL 120mg SC q4w + cirurgia curettage + cimenta\u00e7\u00e3o PMMA; (e) outros 19%<\/strong> cordoma sacro+base cr\u00e2nio + adamantinoma t\u00edbia + linfoma \u00f3sseo prim\u00e1rio PBL DLBCL + mieloma m\u00faltiplo + met\u00e1stase mama+pr\u00f3stata+pulm\u00e3o+rim+tireoide + estadiamento Enneking+MSTS + TNM 8\u00aa.<\/p>\n

Cl\u00ednica com A1 osso madura garante margem R0 wide local<\/strong> + previne recidiva local<\/strong> + otimiza preserva\u00e7\u00e3o membro limb-salvage<\/strong>. Como discutimos no post sobre sarcoma partes moles<\/a>, A1 sarcoma \u00e9 base.<\/p>\n

A4 ressec\u00e7\u00e3o wide local + endopr\u00f3tese MUTARS\/Stanmore\/GMRS + amputa\u00e7\u00e3o: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) ressec\u00e7\u00e3o wide local R0<\/strong> com margem 2-5cm tecido normal + EMBI Enneking Musculoskeletal Tumor Society + bi\u00f3psia tract excis\u00e3o + planejamento RM\/CT preoperat\u00f3rio + freezing intraoperat\u00f3rio margem; (b) endopr\u00f3tese tumoral mega-pr\u00f3tese<\/strong> com MUTARS Modular Universal Tumor And Revision System Implantcast Alemanha + Stanmore Implants Reino Unido + Howmedica\/Stryker Megaprosthesis GMRS Global Modular Replacement System + Zimmer Biomet Compress + R$ 80-150k + adolescente expandable extensible Repiphysis Wright; (c) alotransplante \u00f3sseo allograft<\/strong> com banco osso humano + osteoarticular + intercalar + composto allograft-prosthesis APC + risco infec\u00e7\u00e3o 10-25% + uni\u00e3o pseudoarthrose 5-15%; (d) amputa\u00e7\u00e3o<\/strong> com indica\u00e7\u00e3o tumor irressec\u00e1vel + invas\u00e3o vascular maior + invas\u00e3o nervosa maior + recidiva local p\u00f3s-cirurgia + amputa\u00e7\u00e3o supracondiliana f\u00eamur + transtibial + hemipelvectomia interna\/externa Hibbs+Gordon-Taylor; (e) rotacionplastia Van Nes<\/strong> com osso intermedi\u00e1rio ressecado + tornozelo rotacionado 180\u00b0 funcional como joelho + adolescente preservar fun\u00e7\u00e3o + alternativa amputa\u00e7\u00e3o supracondiliana.<\/p>\n

Cl\u00ednica com A4 ressec\u00e7\u00e3o+endopr\u00f3tese madura escala R0 80-90%<\/strong> + previne falha endopr\u00f3tese 10-20% 5y<\/strong> + otimiza limb-salvage 70-90%<\/strong>. Conex\u00e3o com ortopedia esportiva<\/a>.<\/p>\n

MAP osteossarcoma + VDC\/IE Ewing + denosumab GCT + Sm-153\/Ra-223: o est\u00e1gio quimio+radio+targeted<\/h2>\n

A terceira camada \u00e9 MAP+VDC\/IE+denosumab+radio. Padr\u00e3o setorial inclui (a) MAP osteossarcoma adjuvante<\/strong> EURAMOS-1 + cisplatina Platinol 120 mg\/m\u00b2 + doxorrubicina Adriamycin 75 mg\/m\u00b2 + MTX metotrexato altas doses 12 g\/m\u00b2 + leucovorin rescue + ifosfamida+etoposide salvage IE; (b) VDC\/IE Ewing alternating<\/strong> vincristina+doxorrubicina+ciclofosfamida + ifosfamida+etoposide + 14-17 ciclos + 6-12 meses tratamento + AEWS0031+EE2012 protocolos colaborativos + RT consolidativa 45-55,8 Gy; (c) denosumab Xgeva Amgen GCT<\/strong> anti-RANKL monoclonal 120mg SC q4w + redu\u00e7\u00e3o tamanho 80-90% + osteonecrose mand\u00edbula ONJ risco 1-2% + hipocalcemia + recidiva p\u00f3s-suspens\u00e3o; (d) sarcoma \u00f3sseo avan\u00e7ado\/metast\u00e1tico<\/strong> com sunitinib Sutent+pazopanib Votrient SARC024+regorafenib Stivarga+sorafenib+cabozantinib Cabometyx+denosumab+olaratumab Lartruvo PDGFR\u03b1+pembrolizumab Keytruda PD-1+nivolumab+ipilimumab+trabectedina Yondelis+eribulina Halaven Lista C5; (e) Sm-153 EDTMP Quadramet met\u00e1stase \u00f3ssea<\/strong> Lantheus 37 MBq\/kg IV + Ra-223 Xofigo Bayer alfa-emitter 50 kBq\/kg IV q4w \u00d7 6 + I-131 MIBG neuroblastoma + decaimento + IPEN\/CNEN-NN-3.05.<\/p>\n

Cl\u00ednica com MAP+VDC\/IE+denosumab+radio madura escala OS osteossarcoma EFS 60-70%<\/strong> + escala OS Ewing localized 75-80%<\/strong> + escala denosumab GCT downstaging 80-90%<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade osso<\/h2>\n

Cl\u00ednica osso s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 8.000-24.000<\/strong> mas perda de A4+C+E+sist\u00eamico.<\/p>\n

Cl\u00ednica osso A1 + A4 + MAP\/VDC.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + quimio.<\/p>\n

Cl\u00ednica osso 5 fluxos completos.<\/strong> A1+A4+C+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa osso + endopr\u00f3tese MUTARS limb-salvage + denosumab GCT.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica osso<\/h2>\n

O primeiro \u00e9 a subdimensionamento Lista C5 quimio sarcoma<\/strong>. Sem segrega\u00e7\u00e3o MAP+VDC\/IE+denosumab+sunitinib+pazopanib+regorafenib+olaratumab+pembrolizumab+trabectedina+eribulina + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada.<\/p>\n

O segundo \u00e9 a mistura A1 osteossarc + Ewing + condrossarc + GCT<\/strong>. Confunde rastreabilidade tumor + impossibilita Enneking+MSTS+TNM + risco indica\u00e7\u00e3o inadequada quimio (MAP vs VDC\/IE vs denosumab vs targeted).<\/p>\n

O terceiro \u00e9 a falta de protocolo endopr\u00f3tese MUTARS rastreabilidade<\/strong>. Sem rastreabilidade Implantcast+Stanmore+Howmedica+Stryker+Zimmer Biomet + ANVISA tecnovigil\u00e2ncia + IFRS 16 leases comodato = risco breach + zero auditoria + risco recall.<\/p>\n

A regula\u00e7\u00e3o de PGRSS osso no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer \u00d3sseo<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS osso 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 osteossarcoma OST 35% adolescente+jovem+met\u00e1fise f\u00eamur distal+osteobl\u00e1stico+condrobl\u00e1stico+telangiect\u00e1sico+Ewing ES 16% adolescente+di\u00e1fise+EWSR1-FLI1 t(11;22) 85%+EWSR1-ERG+CD99+Askin t\u00f3rax+condrossarcoma CS 25% adulto+bacia 30%+G1-G3+desdiferenciado+IDH1\/2 50%+GCT 5% ep\u00edfise+RANKL+denosumab+cordoma+adamantinoma+PBL+mieloma+met\u00e1stase+Enneking+MSTS+TNM 8\u00aa+CID C40-C41, A4 ressec\u00e7\u00e3o wide local R0 margem 2-5cm+EMBI+endopr\u00f3tese MUTARS Implantcast Alemanha+Stanmore Implants UK+Howmedica\/Stryker GMRS Global Modular Replacement+Zimmer Biomet Compress+R$80-150k+Repiphysis Wright extensible+allograft osso+APC+amputa\u00e7\u00e3o supracondiliana+hemipelvectomia interna\/externa Hibbs+Gordon-Taylor+rotacionplastia Van Nes 180\u00b0+limb-salvage 70-90%, C Sm-153 EDTMP Quadramet Lantheus 37 MBq\/kg+Ra-223 Xofigo Bayer 50 kBq\/kg\u00d76+I-131 MIBG neuroblastoma+CNEN-NN-3.05+IPEN, E bi\u00f3psia core 14G+Tru-Cut+Jamshidi+aberta incisional+freezing intraoperat\u00f3rio+Mohs, sist\u00eamico MAP osteossarcoma EURAMOS-1 cisplatina+doxorrubicina+MTX altas doses+leucovorin rescue+VDC\/IE Ewing AEWS0031+EE2012 14-17 ciclos+RT 45-55,8 Gy+denosumab Xgeva Amgen anti-RANKL+sunitinib Sutent+pazopanib Votrient SARC024+regorafenib Stivarga+olaratumab Lartruvo PDGFR\u03b1+pembrolizumab Keytruda PD-1+trabectedina Yondelis+eribulina Halaven Lista C5.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS oncologia osso: osteossarc + Ewing + condro + endopr. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2243,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,3079,3078,2910],"class_list":["post-2244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-ewing","tag-osso","tag-osteossarcoma"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2244"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2244\/revisions"}],"predecessor-version":[{"id":4345,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2244\/revisions\/4345"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2243"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}